Prognostic Value of Lactate Dehydrogenase in Second-Line Immunotherapy for Advanced Esophageal Squamous Cell Carcinoma

Background: Immunotherapy is recommended by the NCCN (National Comprehensive Cancer Network) guidelines as the standard second-line treatment for advanced esophageal squamous cell carcinoma (ESCC). Patients with advanced ESCC can benefit from immunotherapy, but the overall survival time (OS) is stil...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yan, Wang, Kunlun, Zhao, Erjiang, Li, Bingxu, Li, Shenglei, Dong, Xiaotao, Yuan, Ling, Yang, Hui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pathology and Oncology Archive
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9203685/
https://www.ncbi.nlm.nih.gov/pubmed/35721326
http://dx.doi.org/10.3389/pore.2022.1610245

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9203685/
https://www.ncbi.nlm.nih.gov/pubmed/35721326
http://dx.doi.org/10.3389/pore.2022.1610245

Ejemplares similares